<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by EpiPredict on Medium]]></title>
        <description><![CDATA[Stories by EpiPredict on Medium]]></description>
        <link>https://medium.com/@EpiPredict?source=rss-a09b235adc53------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*GsPZYPTlamdTot8Vay4kWg.png</url>
            <title>Stories by EpiPredict on Medium</title>
            <link>https://medium.com/@EpiPredict?source=rss-a09b235adc53------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 17:47:12 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@EpiPredict/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Your Immune System : A friend or a foe?]]></title>
            <link>https://medium.com/@EpiPredict/your-immune-system-a-friend-or-a-foe-51acb814d21e?source=rss-a09b235adc53------2</link>
            <guid isPermaLink="false">https://medium.com/p/51acb814d21e</guid>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[immunotherapy]]></category>
            <dc:creator><![CDATA[EpiPredict]]></dc:creator>
            <pubDate>Mon, 18 Feb 2019 08:01:00 GMT</pubDate>
            <atom:updated>2019-02-18T14:46:21.390Z</atom:updated>
            <content:encoded><![CDATA[<h3><strong>Your Immune System : A friend or a foe?</strong></h3><p><em>Written by EpiPredict PhD fellow, Anchal </em>Nigam <em>(Epiontis, DE), together with EpiPredict Partner Organisation </em><a href="http://www.science-matters.eu/"><em>Science Matters</em></a><em>. The </em><a href="http://www.epipredict.eu/"><em>EpiPredict consortium</em></a><em> receives funding from the EU Horizon 2020 program under Marie Sklodowska-Curie grant agreement no. 642691.</em></p><p>“Your worst enemy could be your best friend &amp; your best friend your worst enemy” - Bob Marley</p><p>It is difficult to recognize an enemy in disguise and especially when the enemy is hidden amongst friends. Nevertheless, the human body has to deal with such scenarios. Our body is invaded by millions of pathogens* such as bacteria, viruses, toxins and sometimes suspicious growth of cells (for further explantion see the glossary below). Luckily our bodies have developed a sophisticated immune system to deal with such invasions.</p><p>The immune system is a well-organized battalion of soldiers, comprising of cells that circulate throughout the body, reaching every organ. The cells of the immune system can be divided into two classes. One class of cells is constantly on the lookout for invaders and skeptically growing cells. When the enemies are recognized, they are eliminated or their activity is neutralized. We call these immune cells the “protectors” of the body. Examples of “protector” immune cells are effector T and B lymphocytes*, dendritic cells*, natural killer cells*. However, the protectors sometimes lack the ability to differentiate between the ‘good’ and the ‘bad’ cells. Therefore, the activity of these protector cells need to be monitored. Just to prevent them from attacking the good cells, which might lead to a dangerous condition called autoimmunity.</p><p>The second class of immune cells is also known as “immune regulators”. Like the name suggests, these cells regulate the development and the activity of the protectors. Some examples of these type of cells are Regulatory T cells(Tregs)*, Myeloid-derived suppressor cells (MDSC)*. In normal conditions, nature maintains the cells of both classes of the immune system in a balance just like a see-saw (figure below). The protector cells recognize as a team any kind of enemy and attack it, while on the other side the regulatory cells balances the number of protector cells to prevent them from attacking the good cells. However sometimes the number of regulatory cells increase drastically due to chemicals secreted by some developing tumor cells or pathogens. As a consequence the regulatory cells outweigh the protector cells and thereby disturb the balance. The body is now less protected from invasions, because the excess of regulatory cells prevent too many protector cells to perform their function. This paves the way for bad cells to grow without inhibition. We could say that these regulatory cells turned into<strong> foes. </strong>This situation gives a tumor an ideal environment to escape the immune supervision. Subsequently the tumor will grow and spread (metastasis*) to attack other organs.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/448/1*YNUcncovQB_L_PRLSQa-VQ.png" /><figcaption><strong>Figure: <em>“It is all about balance”</em>. </strong>In a “balance” condition, the protectors are on the lookout of any harm causing agent, and the regulators maintain the levels of protectors . In this figure, the balance has shifted towards regulators. Increase of regulators results in outweigh of regulators over protectors. This would give a good chance for the naive tumor to grow, develop and metastasize.</figcaption></figure><p>Many clinical and laboratory studies have suggested that an increased number of regulatory immune cells might be a cause of tumor growth and metastasis of many cancers such as lung, pancreas, colon (Jiang Y <em>et.al.</em>, 2015, Turbachova <em>et.al.</em>, 2013, Liu <em>et.al.</em>, 2018). The signature of high levels of immune regulatory cells have also been reported in recurrence of the tumor* (Bense<em> et.al.</em>, 2017, A. Hendel, 2018). In these cases, the cells from women with recurrent breast cancer had a much weaker immune response compared to the cells of women whose breast cancer had not recurred. The protector immune cells along with the help of anti-tumor drugs once fought against the growing cancer cells and was successful to kept it at a bay. Unfortunately after 5–10 years of treatment it was unable to mount the attack against the recurrent tumor. The thinking is that the patient’s protector cells somehow become exhausted or stop responding. Why and how this occurs is still unknown.</p><p>In our project called EpiPredict, we try to understand why the protector cells stop working in this group of patients before they relapse. For that we are applying very specific epigenetic technology* to count systematic changes in the make-up of the immune cells from both types (protector &amp; regulator) in patient samples. The changes of both classes are compared to healthy cells to understand the nature of the tumor and to predict the risk of relapse. This would be a major advancement in the field of diagnosis of breast cancer and would help the clinicians to provide the patients with appropriate treatment.</p><p>The knowledge of immune cell regulation has also been an inspiration for many scientists to develop treatment against tumors. For example to reduce the excess of regulators or to stimulate the protectors to fight the growing tumor. Such therapies are called as cancer immunotherapy. Notably, this year the <a href="https://www.nobelprize.org/prizes/medicine/2018/summary/">Nobel Prize in Physiology and Medicine </a>was awarded to the discovery of cancer therapy by inhibition of negative immune regulation. This involved the finding a peculiar composition of protector cells by the two scientists James P. Alisson and Tasuku Honjo. They found that the cells were presenting two proteins CTLA-4 and PD-1, which prevented their antitumor activity. Imagine two additional elements attached to the cells that stops their ability to attack a tumor. This research led to development of drugs blocking the additional CTLA-4 and PD-1 pieces, which empowered the immune action against the tumor.</p><p>Immune cells might be the biggest fighters in the body to protect you, but they can turn into foes. How and why they turn is often a mystery. Knowledge about these cells help us to understand more and more about their involvement in cancer. And in some cases this has led to the development of diagnostics and therapies which is a bright light cutting through the grey clouds of cancer.</p><p><strong>Glossary</strong></p><p><strong>*Pathogen: </strong>They are the microorganisms which have an ability to cause disease.</p><p><strong>*Cancer: </strong>It is a disease, in which cells starts multiplying in number and growing unregulated. The cells can invade other organs and also spread to distant organs.</p><p><strong>*Tumor</strong>: It is cancer which occurs in solid tissues like organs, bone or muscle.</p><p><strong>*Metastasis</strong>: It is the phenomenon where cancer cells invade other organs by growing blood vessels and spread to distant organs via blood. As this stage the tumor is said to be malignant and is a danger to the body.</p><p><strong>*T lymphocyte (a.k.a T cells)</strong>: They are a type of white blood cells which are an important part of the “protector” class of the immune system. They either secrete chemicals to kill foreign harmful elements in the body or assist in killing them. They create a memory of an invasion that remembers the intruder and is prepared at the time of re-invasion.</p><p><strong>*B Lymphocytes (a.k.a B cells): </strong>They are a type of white blood cells which are an important part of the “protector” class of the immune system. With the help of T cells, they recognize a particular protein called an antigen, present on the foreign intruder and attacks them by secreting a protein called an antibody which is specific for that particular antigen. They also form <strong>memory cells</strong> that remember the same pathogen for faster antibody production in future infections.</p><p><strong>*Natural Killer Cells</strong>: They are a type of white blood cells, which provide rapid immune attack on a cell invaded by virus or against tumors. They have a self-ability to recognize cells that are in trouble.</p><p><strong>*Dendritic Cells</strong>: They are a class of accessory cells also known as antigen presenting cells and they help the T cells and B cells to recognize the antigen protein present on the invading pathogen.</p><p><strong>*Regulatory T cells (Tregs)</strong> : They are a type T cells which have a specialised function to control and regulate the T cells activity and prevent them to attack the “good cells”. They have the power to suppress the growth of T cells or even help them die. They belong to class of “regulators”.</p><p><strong>*Myeloid derived suppressor cells (MDSC) : </strong>Like Tregs, they also have a function to control and regulate the activity of “protector cells” . They help Tregs in their task. They belong to class of “regulators”.</p><p><strong>*Recurrence of tumor: </strong>A recurrence of tumor occurs when the cancer comes back after treatment. This can happen weeks, months, or even many years after the original cancer was treated.</p><p><strong>*Stage of tumor</strong>: It describes where a cancer is located, if or where the cancer cells have spread, and whether the cancer has affected other parts of the body. This is important information for clinicians to know the extent to which the cancer has infected the body.</p><p><strong>*Diagnosis </strong>: The identification of the nature of an illness or other problem by examination of the symptoms</p><p><strong>*Epigenetics : </strong>This is the study of changes upon the genetic code (DNA), an extra layer of code. This layer could be proteins which wrap around DNA thereby blocking certain regions of DNA or a chemical change on certain component of DNA. These extra parts on the DNA can influence its function; they are very stable, non-volatile and are hereditary in nature. In one of the previous blogs, “<a href="https://medium.com/@EpiPredict/can-you-control-your-genes-yes-you-can-with-epigenetics-7e82bab567d5">Introduction to Epigenetics</a>” written by fellows in our project consortium, you can find more information about this topic.</p><p><strong>*Chemo and radio therapy : </strong>They are chemicals or radiations given independently or in combination to a cancer patient to kill the cancer cells. They are widely practiced technique help in survival against cancer but also have side-effects.</p><p><strong>References</strong></p><p>· Turbachova et al. <em>Epigenetics</em>. 2013;8(11):1226–1235. The cellular ratio of immune tolerance (ImmunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.</p><p>· Barth et al., JNCI J Natl Cancer Inst 2015, 107(11): Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg</p><p>· Baron et al., Sci. Transl. Med. 10, eaan3508 (2018). Epigenetic immune cell counting in human blood samples for immunodiagnostics</p><p>· Jiang Y. et.al. Cell Death Dis. 2015T-cell exhaustion in the tumor microenvironment.</p><p>· Liu Y et. al. Cancer Immunol Immunother. 2018 Aug;67(8):1181–1195. Targeting myeloid-derived suppressor cells for cancer immunotherapy.</p><p>· Nielsen et al. Clin Cancer Res.2010;16(21):5222–5232.A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.</p><p>· Bense et al. J Natl Cancer Inst. 2017;109(1). Relevance of tumor infiltrating immune cell composition and functionality for disease outcome in breast cancer.</p><p>· Pitt et. al. Annals of Oncology, 1 August 2016, Volume 27, Issue 8, Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.</p><p>· A.Heindel et.al. JNCI J Natl Cancer Inst (2018)Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence. After Endocrine Therapy of ER1 Breast Cancer</p><p>· Nesrine Mejri et.al., Ther Adv Med Oncol. 2015 May; 7(3): 144–152 Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient’s follow up?</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=51acb814d21e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What we talk about when we talk about CRISPR]]></title>
            <link>https://medium.com/@EpiPredict/what-we-talk-about-when-we-talk-about-crispr-2e9319e44c9?source=rss-a09b235adc53------2</link>
            <guid isPermaLink="false">https://medium.com/p/2e9319e44c9</guid>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[epigenetics]]></category>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[crispr]]></category>
            <dc:creator><![CDATA[EpiPredict]]></dc:creator>
            <pubDate>Thu, 03 May 2018 09:34:09 GMT</pubDate>
            <atom:updated>2018-05-03T09:34:09.935Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Written by EpiPredict PhD fellow, </em>Emre Sofyali<em> (DKFZ, DE), together with EpiPredict Partner Organisation </em><a href="http://www.science-matters.eu/"><em>Science Matters</em></a><em>. The </em><a href="http://www.epipredict.eu/"><em>EpiPredict consortium</em></a><em> receives funding from the EU Horizon 2020 program under Marie Sklodowska-Curie grant agreement no. 642691.</em></p><p>It has not been very long that the world got introduced with the concept of CRISPR — a revolutionary approach on editing the genome. CRISPR is an acronym for Clustered Regularly Interspaced Short Palindromic Repeats. Mouthful, right? Well, basically CRISPR derives its name from the unique stretches of DNA (our unique genetic material) that it targets. These short stretches of DNA are recognized by a special molecule (guide RNA) that forms a complex with an enzyme (Cas9) to bind and induce a cut at the recognized DNA region. The CRISPR system is derived from bacteria where it recognizes virus DNA and digest it into small pieces to make the virus harmless. Now, we use CRISPR in our advantage and specifically engineer the guide RNA to recognize a desired DNA location and make a cut there. This cleavage results in a break in DNA which can be repaired by the cell. However, this break in the DNA helix enables the researchers either to delete or insert pieces of DNA code from or into the target region, respectively (genome editing).</p><p>We can think of CRISPR-Cas9 system as microscopic scissors with an incredible precision. Precision is the key word for this approach since editing of the genome with this level of specificity was not possible before CRISPR. And precision is achieved by aforementioned guide RNA (gRNA) and Cas9 complex that scans through the entire genome to find the exact matching sequence between gRNA and target DNA. We can say that gRNA acts like a GPS to find the ultimate destination through the intricate highways of the genetic material. When the complex reaches the destination, the Cas9 enzyme cleaves the double helix of the DNA and the edits are introduced in the genome.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/728/1*BgWgbl-1gDGOwDHqG6xv7w.png" /><figcaption>Image by Science Matters</figcaption></figure><p>This is not the only approach for genetic engineering that CRISPR system has to offer. There are many studies where the so-called GPS feature of enzyme-gRNA complex is used to recruit proteins. However in that case the cutting properties of Cas9 are disabled (dCas9 — stands for deactivated Cas9). Instead the dCas9 is coupled to proteins that have the potential to activate or inactivate parts of the DNA. Before giving an example for this aspect of CRISPR approach let me tell you a little bit more about our research.</p><p>In the frame of the EpiPredict consortium, we make use of the CRISPR system by utilizing it as a tool for interfering with the layer on top of genetic code. We will refer to this layer as epigenetic layer from now on just to keep the fancy mouthful scientific jargon intact. Well, if we try to explain simply, genes in our DNA code for the proteins which in turn perform functions to sustain life. There are many factors that may affect the activity of a gene and one of these factors is the environment in which a gene is located. Different environments in the DNA may sound a bit strange, but you have to know that the DNA strand is not just a long stretched out strand, but it is wrapped around proteins which can be chemically altered to allow or block access of certain DNA regions. Also the DNA itself can get chemical modifications that may affect its activity. If you wish to know more about what epigenetics is in a nutshell, here is a very nice blog that might be considered as “<a href="https://medium.com/@EpiPredict/can-you-control-your-genes-yes-you-can-with-epigenetics-7e82bab567d5">Introduction to Epigenetics</a>” written by fellows in our project consortium.</p><p>In our project, we are mainly interested in uncovering what underlies the resistance to hormone therapy in a certain subtype of breast cancer. In this case the therapy is working at first, but after a while the treatment response is lost. We have reasons to believe that alterations in the above mentioned epigenetic layer might play an important role in this development of resistance against the hormone treatment. That is why we are looking for therapeutic cues to interfere with this layer aiming to reverse the resistance and re-sensitize the cancer cells to the therapy. For that, we perform epigenetic interference by using the highly specific CRISPR/dCas9 tool. This system enables us to temper with the modifications on or around the DNA and thereby change activity of genes in a targeted manner.</p><p>Still confusing, right? Let me try to elucidate with an example:</p><p>Imagine gene X is known to be impaired in the acquired resistance against the hormone therapy and re-activation of gene X is able to return sensitivivty to the therapy which means a patient can benefit again from the conventional therapy. To induce the activity of gene X we can target the region of DNA that codes for gene X with CRISPR/dCas9. In this way dCas9 fused with specific epigenetic marker modifiers (epi-modifiers) is recruited. The attached epi-modifier removes modifications associated with repression and/or introduces modifications associated with activation. Hereby we change the genomic environment of gene X resulting in re-activation.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/746/1*JR-cD_Nz2JnNzRbo1h0w-g.png" /><figcaption>Image by Science Matters</figcaption></figure><p>Targeted re-writing of epigenetic modifications might give the opportunity to alter or fine-tune the activity of target genes. Although there are many technical hurdles that need to be overcome about the technology itself and ethical questions regarding usage of CRISPR in treating human diseases, it is beyond any question that this cutting-edge technology has a lot to offer in terms of (epi)genetic editing.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2e9319e44c9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Every scientist should meet a patient]]></title>
            <link>https://medium.com/@EpiPredict/every-scientist-should-meet-a-patient-657b111ddc4d?source=rss-a09b235adc53------2</link>
            <guid isPermaLink="false">https://medium.com/p/657b111ddc4d</guid>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[scientist]]></category>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[patient-engagement]]></category>
            <category><![CDATA[epigenetics]]></category>
            <dc:creator><![CDATA[EpiPredict]]></dc:creator>
            <pubDate>Tue, 13 Feb 2018 12:00:23 GMT</pubDate>
            <atom:updated>2018-02-13T14:09:51.757Z</atom:updated>
            <content:encoded><![CDATA[<h4>Insides from Breast Cancer researcher Dr Luca Magnani</h4><p><em>Written by EpiPredict PhD fellow, Simone Borgoni (DKFZ, DE)</em></p><p><strong>Studying breast cancer is a big challenge and does not only require hard work from scientists: patients can help as well to make progress. At the end of last year, with the EpiPredict consortium we organized as outreach event a science cafe meeting, where researchers and breast cancer patients exchanged their experience on breast cancer treatment. To learn more about patient-researcher interactions, I spoke with Dr Luca Magnani, who is regularly attending these events.</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/339/1*Mn_UhRWJ5yoTxytMu00ZWw.png" /><figcaption>Dr Luca Magnani</figcaption></figure><p><strong><em>Who is Dr Luca Magnani?</em></strong></p><p><em>Dr Luca Magnani received his PhD from Purdue University (USA). In 2013 he moved to the Department of Surgery and Cancer at Imperial College London (ICL, UK) to take up a Junior Research Fellowship. He is now a senior research fellow supported by a CRUK career development fellowship. He leads a team of researchers focused on the causes of resistance to hormone therapies in breast cancer.</em></p><p><strong>Why did you decide to focus your research on breast cancer?</strong></p><p>“After my doctorate I started working in a laboratory that focused on breast cancer and I found it really intriguing and challenging. When I had the opportunity to set up my own lab in ICL I decided to keep my research line on breast cancer, particularly trying to understand the role of epigenetics in the disease progression and resistance to therapies”.</p><p><strong>With epigenetics you mean…</strong></p><p>“Epigenetics is a layer of information on top of the ones written in the DNA sequence (genetics) that is essential to determine the fate and behaviour of our cells. The peculiarity of epigenetics is its dynamic and reversible property, in contrast to the DNA code that is fixed in our cells”.</p><p><strong>One of the crucial issues that you focus on is resistance to drugs targeting the cancer cells. How do you see the importance of epigenetics over genetics in the context of therapy resistance?</strong></p><p>“Indeed resistance to standard anti-cancer therapies is a major issue. For year researchers have studied genetics to find answers in the difference in the DNA sequence between patients. Investigating epigenetics on the other hand is relatively new and many resources are now flowing into this direction. I think that neither genetics nor epigenetics is uniquely important in tumour evolution and therapy resistance, but rather they influence each other. Increasing our understanding of both of them and particularly their interaction is essential to unravel the complexity of tumour evolution”.</p><p><strong>Since 2015 you are involved in the EU Horizon 2020 funded EpiPredict consortium. This involves 15 partners, both academic and non-academic, across 8 different countries. What are the advantages of working in an interdisciplinary and international consortium?</strong></p><p>“It is very stimulating to be confronted with others and working together to reach the same goal. I particularly like the feeling “to be out of the comfort zone”. For example in this consortium we are confronted with people from different countries and other ways to do science. Each of us has specific strengths and weaknesses and we all bring them to the table to be shared with each other. Combining our expertise, we make a great team. Last but not least, it is always much more fun working and joking together”.</p><p><strong>As a scientist, your work is mostly confined in the lab, far from the clinic where breast cancer patients are treated. For this reason tissue availability is a major issue in scientific research. What do you have to do to get material you need to continue your research?</strong></p><p>“Obtaining patient material to study is indeed a major problem. Such materials can be acquired by means of a biopsy, in which a surgeon removes a bit of the tumour cells. This procedure only takes place when it directly benefits patients, which makes it difficult for research. For us it would be best to have additional samples at various stages during the disease progression. But no surgery is performed when this is necessary for sole research purposes. Moreover all the biopsies are taken before drugs administration. This is not ideal, particularly in our line of research that involves understanding the mechanism of therapy resistance”.</p><p><strong>Do you have any suggestions or maybe wishes on how to change this process?</strong></p><p>“Ideally, the best sampling procedure for research purposes would involve 3 biopsies: one before surgery, one after drug administration for disease check-up and eventually one after recurrence development. Obviously I say this as a scientist. I know biopsies are invasive and are quite harsh on the patients. This is also the reason that at the moment the check-ups are mostly performed with imaging techniques as MRI. However, I think performing biopsies would benefit the patients as well by getting immediate and specific information on the molecular characteristic of the tumours. The depth of information that could be obtained from biopsies can hardly be achieved by the mere image obtained from MRI screening. In order to improve the way tissues are collected for research purposes there should be more crosstalk between scientists and clinicians to find a more structural strategy that could benefit both patients in the immediate term and research in the long term”.</p><p><strong>To have a closer connection between research and clinic you actually started to meet breast cancer patients. How did this begin? And how are these meetings organized?</strong></p><p><strong>“</strong>The research in my lab is funded by several funding agencies, amongst others the <em>EU Horizon 2020 and </em>Cancer Research UK (CRUK). The latter has a patient engagement policy and therefore we set up lab visits for interested patients. During one of those visits I got to know some patients that set up a charity to bring (ex)-patients and researcher together. One thing led to another and I started to join these meetings. You should keep in mind that as a scientist you don’t usually get opportunities to interact with patients, but these meetings are exactly filling this gap. However meeting with patients is not trivial. We as lab researchers are not trained to engage people with serious illness and this can be difficult to deal with for both sides. To be prepared for this experience we first met with a Senior Nurse at CRUK who thought us how to approach and talk to patients”.</p><p><strong>What are the additional values that this close contact with patients brings to your work?</strong></p><p>“The main additional value is definitely motivation. In these meetings you are reminded why you are doing research. Sometimes in the lab you tend to forget that and you are producing results only for career purposes. This would be incredibly limiting as in the end we all started this job with the dream of new discoveries that will save lives. We are not expecting new ideas or biological inputs from the patients but more a personal social involvement that is sometimes lacking in our researchers’ daily work. Another practical advantage of these meeting is confronting on clinical trials. These are set up by clinicians and researchers without usually considering the opinions of patients on several issues: are they willing to give samples for research, and if yes what side effect are they willing to face, how many visits to the hospital do they want to go through for sampling and checking and so on. It is important that doctors and scientists can consider these variables as well when making decisions for new clinical trials”.</p><p><strong>What are the challenges to get closer to patients?</strong></p><p>“The challenges are mainly emotional. You are facing death: it is scary and overwhelming. We are working mainly with cell lines in a plastic dish and they don’t give back any reaction or feeling. You learn how to empathize with patients. Interestingly, not everybody reacts in the same way: different people approach these meetings in their own way. After all, I think it is really personal but it is a strong experience and every student should be exposed to it early in her or his career”.</p><p><em>This blog was established in collaboration with EpiPredict Partner Organisation </em><a href="https://medium.com/u/35ea9d60a749"><em>Science Matters</em></a><em> (</em><a href="http://www.science-matters.eu/"><em>www.science-matters.eu</em></a><em>). The EpiPredict consortium (</em><a href="http://www.epipredict.eu/"><em>www.EpiPredict.eu</em></a><em>) receives funding from the EU Horizon 2020 program under Marie Skłodowska-Curie grant Innovative Training Network agreement no. 642691.</em></p><p>Dr Magnani is an invited speaker at the conference Systems Epigenetics: Towards Precision Cancer Medicine, to be held in Amsterdam, the Netherlands, 27–30 November 2018, organized by the EpiPredict consortium. See the conference website <a href="http://www.systemsepigenetics2018.eu/">here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=657b111ddc4d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Behind the scenes — Interview with a female data scientist who is studying data of breast cancer…]]></title>
            <link>https://medium.com/@EpiPredict/behind-the-scenes-interview-with-a-female-data-scientist-who-is-studying-data-of-breast-cancer-cd0ea831663c?source=rss-a09b235adc53------2</link>
            <guid isPermaLink="false">https://medium.com/p/cd0ea831663c</guid>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[epigenetics]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[phd]]></category>
            <category><![CDATA[big-data]]></category>
            <dc:creator><![CDATA[EpiPredict]]></dc:creator>
            <pubDate>Tue, 19 Dec 2017 14:21:41 GMT</pubDate>
            <atom:updated>2017-12-19T14:21:41.914Z</atom:updated>
            <content:encoded><![CDATA[<h3><strong>Behind the scenes — Interview with a female data scientist who is studying data of breast cancer cells.</strong></h3><p><strong>Maryam Soleimani Dodaran is a PhD student within the European research consortium EpiPredict and works at the</strong> <strong>Swammerdam Institute for Life Sciences in the Netherlands. Epipredict is a collaboration between 15 research institutes and companies to understand and predict why some breast cancer patients develop resistance to hormone therapy.</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/240/1*DfSYGd1Kf_LoYvQJvfb2YQ.jpeg" /><figcaption>Maryam Soleimani Dodaran</figcaption></figure><p><strong>To start off, can you tell us what is your role in this ambitious international research effort?</strong></p><p>I am a data scientist for EpiPredict, which means I am dealing with a lot of DNA data. We want to understand why patients could become resistant to a certain breast cancer therapy and we believe the answer lies in studying differences in genetics (DNA), but also epigenetics (for example switches on the DNA that turn genes on and off).</p><p><strong>Ok, wait a minute. Epigenetics, can you explain that a bit more?</strong></p><p>Epigenetics is the layer on top of the DNA that is involved in the functioning of the molecular code of A, T, C and G’s. Part of its known function is turning genes on and off. Genes are the parts in the DNA that code for proteins. These proteins perform all the functions in living cells. You have to imagine that not all DNA is constantly active. Some genes are only active under certain conditions, for example they could be activated in the presence of a drug. If you want to learn more about epigenetics, some EpiPredict fellows wrote a nice blog about this topic that you can read <a href="https://medium.com/@EpiPredict/can-you-control-your-genes-yes-you-can-with-epigenetics-7e82bab567d5">here.</a></p><p><strong>Alright, back to your data. How much data are we talking about?</strong></p><p>We are talking about huge amounts of data. Data measured on the level of a whole genome is always big. To give you an idea, one human genome sequence is ~3 gigabase and contains ~20,000 genes. If we would only save the data for activity of these 20,000 genes, it means that we have to save 20,000 values (1 for each gene) for each patient sample. You can imagine, this causes the database to grow very fast in size. Then, we would add even more data concerning epigenetics, we would end up with an even bigger data set.</p><p><strong>Where is all of that data actually coming from?</strong></p><p>Big international consortia could be one of the valuable sources of data. Such big data sets are expensive to produce and maintain, therefore there are special organizations that handle this task.</p><p>Let me give you an idea of what I am talking about. In an attempt to study different types of cancer, The Cancer Genome Atlas (TCGA) profiled 7 different datatypes (e.g. DNA sequence, gene measurements, protein measurements, etc.) for 33 different tumor types (e.g. breast, liver, lung) from 11,000 patients. The data from this study can be saved on no less than 212,000 DVDs! But it is a very valuable asset to study cancer.</p><p>Our EpiPredict consortium is also generating a dataset for breast cancer by profiling epigenetic datatypes. For example, we map specific changes on the DNA known to influence the activity of genes. This data will hopefully help us answer more specific questions.</p><p><strong>Why is it interesting to search through all of that data? What questions are you trying to answer?</strong></p><p>There are several questions we can try to answer with this data. For example; Could we identify the cause of resistance to therapy in breast cancer? Resistance may be the result of a change in the DNA or a change in the activity of a gene. But finding the changes that cause cancer is not an easy task because our genetics and especially epigenetics change all the time. Not all of these changes cause cancer, so we have to try to find the changes that matter. At the moment, we have new technologies that provide us with tools to edit our DNA and epigenetics. When we find a potential harmful change in the data, we can mimic this in the lab by editing the (epi)genome in a similar manner. In this way, we can verify if the identified change was causal for the cancer. The dream is that one day in the future we can edit the (epi)genome of a patient back to normal as a treatment.</p><p><strong>So, this could potentially help individual patients?</strong></p><p>Yes, that is possible. It is true that prognosis for two cancer patients could be the same but in reality, these patients could have a unique (epi)genetic profile and may therefore benefit from different therapies. Using the (epi)genetics data that has been measured for each patient could hopefully lead us to a tailored therapy based on the (epi)genetic profile of each patient individually.</p><p><strong>I can imagine it’s quite challenging to make sense of all that data. What is your biggest challenge?</strong></p><p>The sheer size of the data sets is challenging to download and store. Often these data sets contain fields that you don’t use and the structure of the stored data is not per se efficient for the purpose of your study. It already takes quite some time to curate the data set. Digging through these big datasets also relies on powerful servers to run the time consuming repetitive processes on the data.</p><p><strong>Is it cool to be a scientist?</strong></p><p>It is cool when we find new leads in our data! In every profession, there are moments of repetitiveness and boredom or hardship. There are definitely times that I cannot find any substantial result and a solution seems to be out of reach. However, any finding, despite all of these problems, makes me feel that I am cracking the code hidden in the big matrices of data. That makes me excited about data science!</p><p>—</p><p><em>This blog was established in collaboration with EpiPredict Partner Organisation </em><a href="http://www.science-matters.eu/"><em>Science Matters</em></a><em>. The EpiPredict consortium (www.EpiPredict.eu) receives funding from the EU Horizon 2020 program under Marie Skłodowska-Curie grant agreement no. 642691.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cd0ea831663c" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Knowledge is power: Would you share your genome data or keep it private?]]></title>
            <link>https://medium.com/@EpiPredict/knowledge-is-power-aef925176644?source=rss-a09b235adc53------2</link>
            <guid isPermaLink="false">https://medium.com/p/aef925176644</guid>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[epigenetics]]></category>
            <category><![CDATA[data]]></category>
            <category><![CDATA[dna]]></category>
            <category><![CDATA[dna-sequencing]]></category>
            <dc:creator><![CDATA[EpiPredict]]></dc:creator>
            <pubDate>Mon, 06 Nov 2017 09:17:35 GMT</pubDate>
            <atom:updated>2017-11-23T15:21:26.371Z</atom:updated>
            <content:encoded><![CDATA[<p><em>This blog was written by two EpiPredict PhD fellows, Désirée Goubert (UMCG, NL) and Stefania Astrologo (UvA, NL), together with EpiPredict Partner Organisation </em><a href="http://www.science-matters.eu/"><em>Science Matters</em></a><em>. The </em><a href="http://www.epipredict.eu/"><em>EpiPredict consortium</em></a><em> receives funding from the EU Horizon 2020 program under Marie Sklodowska-Curie grant agreement no. 642691.</em></p><p>The blueprint of our being is our <a href="https://www.yourgenome.org/facts/what-is-a-genome">genome, our total DNA</a>, which we all inherit from our parents. It holds information about how we look, but also about our health. All of this information is captured in a code written in a precise order of 4 letters at a time, the nucleotides A, C, G, T. Wouldn’t it be cool if we could read our genome as a book and find out hidden traits about ourselves that we never knew before?!</p><p>Nowadays this is actually possible! Recent developments in biotechnology have made enormous progress in the last couple of years to make this happen. When the <a href="https://www.genome.gov/10001772/all-about-the--human-genome-project-hgp/">first</a> complete genome was read, or in technical terms “sequenced”, in 2003 the cost were as high as <a href="https://www.genome.gov/sequencingcosts/">3 billion €</a>. But nowadays whole genome sequencing is accessible to almost everyone, with an approximate cost of 1000 €, a million times less than the initial cost!</p><p><strong><em>Why do scientists want to read DNA and why should you want to do the same?</em></strong></p><p>These low sequencing costs make us scientists very excited, because now we can afford to read the genome of many people. By comparing the genome of thousands of people, we try to decode what the DNA code means. In other words we try to find out which part of the genome is responsible for which particular characteristic. For example, we can compare the DNA code of healthy people with that of patients. The differences can help us to understand the cause of diseases and to try to cure or prevent diseases. When we know what the problem is, we can continue to work on solutions.</p><p><strong><em>Every day, millions of people are taking drugs that won’t make them better</em></strong></p><p>All this sounds really promising, but finding a change (mutation) in DNA that causes a disease is actually a bit more complicated. The reason is that patients with a similar disease are genetically different at many levels. This makes it first of all hard to identify the true cause of the disease in the genome, but, second, the genetic variation among patients can also make them respond differently to the same treatment. Treatments can work for one patient, but not for the other. The numbers at which this happens are shockingly high. Just two years ago, it was stated in <a href="https://www.nature.com/polopoly_fs/1.17411!/menu/main/topColumns/topLeftColumn/pdf/520609a.pdf">Nature (a scientific paper)</a> by Nicholas Schork that “Every day, millions of people are taking medications that will not help them.” The top ten highest-grossing medicinal drugs fail to improve the condition of patients between 96%-75% of the people who take the medication. Importantly, the drugs do work, but only for a small group of the users.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/940/1*T5qPBb1uqQ2ipXtW1kaTHg.png" /><figcaption>Image by Stefania Astrologo</figcaption></figure><p><strong><em>Personalised Medicine: What do we need?</em></strong></p><p>Personalised Medicine aims to overcome this inequality in patients’ treatment, because it takes the uniqueness of the genetic make-up of each patient into account. The genome from patients that do respond and that do not respond to a treatment is compared to find patterns that distinguish the two groups from each other. Once these patterns have been found, they can be used to predict the outcome of a treatment for each individual patient. Important is that the more patient data is available for scientists, the more precise the results will be. At least, scientists already have some knowledge about how various parts in the DNA are regulated together and are functioning as multiple networks that make our bodies work. Also, several networking mutations that cause disease have been identified and there are ideas how these networks may be cured. We expect that the success rate of such personalised treatment will be much higher when compared to conventional treatments. However, sequencing technology is not part of routine medical care yet. To make personalised medicine possible, genetic profiles of thousands of people need to be collected, stored and analysed, and more research on how the networks function is needed. Now that sequencing a complete genome is affordable, creating large libraries containing this genetic information seems to be within reach, but we find another challenge: privacy.</p><p><strong><em>What is the risk of sharing DNA information?</em></strong></p><p>Genomic data are inherently highly sensitive. The more we learn about the DNA code, the better we are able to define diseases, but also the better we become in predicting the risk of developing future diseases. This means that should your DNA code become public, it could be used by health insurance companies, employers and governments in discriminative ways. It is even so that due to the high similarity between genomic data amongst relatives reading the genome of one person can have consequences for all members of an entire family (a notorious example is given by the <a href="https://www.nytimes.com/2017/04/21/well/should-you-worry-about-being-the-next-henrietta-lacks.html"><strong>Lacks family</strong></a>). Only some countries have laws in place that forbid insurance companies to raise premiums for customers with predicted diseases.</p><p>Like the famous Spiderman’s quote teaches us: “with great power comes great responsibility”.</p><p>Interesting enough, many people do not seem to value privacy as the most important aspect. Numerous private companies like 23andMe, Gene By Gene, GeneYouIn, Innova, Illumina offer direct-to-consumer DNA testing kits. You just send a little bit of your spittle and within a few weeks you get back your genetic data, with which one can learn about your heredity, health and disease risk. Keep in mind that the conclusions are not always very accurate. The genomic data of for example 23andme can be shared to search for family members and it seems that many customers have no ethical concerns with this. Also on a daily basis, we gladly share lots of our very personal information without knowing with whom: our social network activities, location data, most visited websites, etc. are sold to <a href="https://www.economist.com/news/special-report/21615871-everything-people-do-online-avidly-followed-advertisers-and-third-party">third parties</a>. Contradictory, when it comes down to sharing sensitive information for research purposes, there is a taboo around privacy and sharing.</p><p><strong><em>Is it really about privacy?</em></strong></p><p>This double standard makes life for researchers a bit hard. Of course we agree that protection of sensitive data is key, but we should like to stress the importance of genomic data for research that can help search for future (clinical) implications. Genomic data for research is treated with special care. For example, all the information originating from patients is coded and anonymous. In this way, the genome profiles cannot be coupled back to a specific person, except if the genome profiles from his/her family members is public.</p><p><strong><em>This is the future</em></strong></p><p>Step by step we are getting closer to a personalised medicine era. One successful example is the <a href="http://www.agendia.com/patient/breast/">MammaPrint</a>, a test that screens individual breast cancer patients for the risk of metastasis. However, at this point in time, most data is still very messy. We need to do much more research with the data we obtain. And our genomic data alone, although fascinating, does not gives us enough information. On top of the DNA letter code, there is a second, so-called epigenetic code. This code reveals information about chemical changes on top of the DNA. Some of these chemical marks are links to active DNA and other to inactive DNA; these links determine which parts of your DNA library is actually used by your cells. Interestingly, this code is much more flexible, the location of chemical marks can for example be influenced by your personal lifestyle and environmental conditions (more information can be found <a href="https://medium.com/@EpiPredict/can-you-control-your-genes-yes-you-can-with-epigenetics-7e82bab567d5">here</a>). Our research in the context of the EU H2020 EpiPredict project is looking at this epigenetic code in breast cancer patients. Like for the DNA code, there are techniques available to read this epigenetic code, giving us more pieces of the puzzle of unravelling the information of (y)our genome. Ideally, in the future the sequencing technologies could be integrated in the clinics as a standard procedure, although it is hard to predict when this will be part of routine care.</p><p><strong>Should you think twice about sharing any of your private genome information?</strong></p><p>Yes, but think about what you share! Whom do you share it with? And what is the information used for? The genome holds the information of your life, in disease and in health, so share wisely.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aef925176644" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Can you control your genes? Yes you can. With epigenetics!]]></title>
            <link>https://medium.com/@EpiPredict/can-you-control-your-genes-yes-you-can-with-epigenetics-7e82bab567d5?source=rss-a09b235adc53------2</link>
            <guid isPermaLink="false">https://medium.com/p/7e82bab567d5</guid>
            <category><![CDATA[dna]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[epigenetics]]></category>
            <dc:creator><![CDATA[EpiPredict]]></dc:creator>
            <pubDate>Tue, 06 Jun 2017 09:39:26 GMT</pubDate>
            <atom:updated>2017-11-05T15:09:56.695Z</atom:updated>
            <content:encoded><![CDATA[<p><em>This blog was written by two EpiPredict PhD fellows, Désirée Goubert (UMCG, NL) and Stefania Astrologo (UvA, NL), together with EpiPredict Partner Organisation </em><a href="http://www.science-matters.eu/"><em>Science Matters</em></a><em>. The EpiPredict consortium (</em><a href="/service/file:///C:/Users/avdlind1/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/QDYAOIEA/www.EpiPredict.eu"><em>www.EpiPredict.eu</em></a><em>) receives funding from the EU Horizon 2020 program under Marie Skłodowska-Curie grant agreement no. 642691.</em></p><p>We all start our lives in the same way, as one single cell, yet we end up as very diverse human beings with 30 trillion cells and 200 different types all with their own unique function!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/714/1*Kl7Zw_DqTTPCcphlEyUJ8A.jpeg" /><figcaption>Image Source: <a href="http://www.tutorvista.com/biology/unicellular-and-multicellular">http://www.tutorvista.com/biology/unicellular-and-multicellular</a></figcaption></figure><p>All the cells in our body contain exactly the same DNA, yet they are not all alike. A nerve cell is clearly different from a muscle cell or a skin cell. How is it possible that cells with exactly the same blueprint end up being so diverse?</p><p>All these interesting questions find its origin in one single term: <strong>epigenetics. </strong>‘Epi-‘ from ancient Greek ἐπί means ‘“on top of”, in this context: a layer on top of the genetic code. An additional form of higher control that determines how the genetic blueprint is read.</p><p>To understand this concept, we have to zoom in to the nucleus of the cell, which is only 6 µm in diameter, where the genetic material is stored. The entire DNA structure has to fit into a tiny structure called the nucleus. You can compare this to wrapping 40 km of fine thread around a tennis ball!</p><p>DNA and histones are even further compacted into a structure called chromatin. The way in which certain genes are tight up by this packing, makes them inaccessible to being expressed.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/942/1*9v0jfrD2A0W197vqdys_pQ.png" /><figcaption>Inactivation and activation of genes</figcaption></figure><p>The level of this packaging for each gene is controlled by <strong>chemical modifications</strong>, which are like traffic lights on the different chromosomes. These traffic lights, or <strong>epigenetic marks</strong>, will determine whether the expression of certain genes is either loosely packed, so ‘<strong>on</strong>’ (green light) or strongly packed and ‘<strong>off</strong>’ (red light) and to what extent they are active. This means that for example in nerve cells, a different pattern of traffic lights and thus a different expression of genes can be found than in muscle or skin cells.</p><p>Most of these epigenetic marks<strong> </strong>are stable from generation to generation. This is why a liver cell will stay a liver cell when it replicates or divides and doesn’t become a muscle or skin cell all of a sudden. However, many of the epigenetic marks are affected by ageing, the environment and even your own lifestyle. This means, we can say goodbye to the general thought that the activity of genes is stable in living beings. Interestingly, this flexibility to changes offers a great opportunity for medicine, because we may be able to intervene with the activity of some genes from the outside. The hope is that disease causing changes in epigenetic marks can be undone.</p><p>To what extend the environment or your lifestyle affects your epigenetic profile is still largely unknown. Also how we can control specific epigenetic marks remains mainly elusive. These questions are currently actively being researched and we expect that more and more will be revealed in the years to come.</p><p>Thus, keep in mind that a long healthy life begins with good genes, but the activity of these genes also depends on good habits!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7e82bab567d5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[From Lab bench to Bed]]></title>
            <link>https://medium.com/@EpiPredict/from-lab-bench-to-bed-fd41b276f9dc?source=rss-a09b235adc53------2</link>
            <guid isPermaLink="false">https://medium.com/p/fd41b276f9dc</guid>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[epigenetics]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[genetics]]></category>
            <dc:creator><![CDATA[EpiPredict]]></dc:creator>
            <pubDate>Fri, 13 Jan 2017 10:41:23 GMT</pubDate>
            <atom:updated>2017-11-05T15:11:20.781Z</atom:updated>
            <content:encoded><![CDATA[<p>How understanding epigenetics could benefit breast cancer patients</p><p><em>This blog was written by EpiPredict PhD fellow, William Beckman (UvA, NL), together with EpiPredict Partner Organisation </em><a href="http://www.science-matters.eu/"><em>Science Matters</em></a><em>. The EpiPredict consortium (</em><a href="/service/file:///C:/Users/avdlind1/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/QDYAOIEA/www.EpiPredict.eu"><em>www.EpiPredict.eu</em></a><em>) receives funding from the EU Horizon 2020 program under Marie Skłodowska-Curie grant agreement no. 642691.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zjHIV0vyXhPJU0MNsAGDJw.png" /></figure><p>Worldwide, 25% of female cancer patients are diagnosed with breast cancer. The majority of those women are positive for the expression of the estrogen receptor. This means that their cancer cells grow in the presence of the hormone estrogen. Generally, this is a “good” prognosis, since there are treatment options available, such as endocrine treatment with drugs as tamoxifen and fulvestrant for premenopausal women or aromatase inhibitors for postmenopausal women. These drugs block or inhibit the action of the estrogen receptor or lower estrogen levels and thereby prevent the tumour from growing further. However, over 20% of the patients expressing hormone receptors show treatment relapse within 10 years to endocrine therapies. To improve and personalize the treatment for breast cancer patients, it is important to understand why some patients become resistant where others do not. Why do cancer cells initially expressing hormone receptors, become resistant to hormone therapy?</p><p>This challenge, of how therapy resistance develops in estrogen receptor positive breast cancer is the key motivation for our scientific research consortium EpiPredict. A team of 12 PhD students from several European institutes and companies combine the latest technologies and insights to find out why these resistant tumours have a different behaviour.</p><p>The answer may be found in the epigenetics of the cell. Epigenetics is the study of changes to the DNA structure that activates or inactivates genes. Interestingly, those modifications do not change the DNA code and can therefore be reversed. So far, most scientists have focussed only on the DNA code of the tumour, to look for mutations in genes that may explain the resistance. But with only genetics the appearance of resistance cannot fully be explained and therefore it is necessary to go beyond the genetic code.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*-tgxavtu7uEyEVqEpCaDpw.png" /></figure><p>To study epigenetics in these resistant tumours, we bring together a broad variety of disciplines like bioinformatics, modelling as well as laboratory research. We will determine the status of several epigenetic markers in different cancer cell lines and in patient tissue. Markers are like flags that are placed at particular places in the genome. The patterns of flags will be sometimes similar and sometimes different among the different samples. Based on these (“flag”) profiles we will test models to see if we can find a correlation of certain marked places in the genome between samples that do respond or do not respond to therapy.</p><p>The interplay between different research fields offers the advantage of having many researchers working synergistically towards a common goal, each bringing its own specific knowledge into the group of a field or technique. This also stresses the importance of good communication between EpiPredict consortium members to ensure that results from separate institutions are comparable.</p><p>However, scientific collaborations are not enough to make our research successful. We are also dependent on the available tissue from patient cohorts that we can use in our research.</p><p>Beyond the need for materials, we aim to let future patients benefit from any of our findings. Our results should be translated from the laboratory into the clinic to be able to improve patients’ treatment plans. Note that — like any scientific research — this is a leap in the dark and it will take many years of thoroughly testing before patients may benefit from it. This doesn’t take away that communication between lab and clinic should be constant to keep the researchers informed what the actual need in the clinic is. Thus, good collaboration between the lab and the clinic is equally important.</p><p>To review these challenges, we will present the first Science café at the German cancer research center (DKFZ) in Heidelberg, Germany, on January 26th 2017. A panel discussion between EpiPredict members and experts in molecular biology and health research will address key questions and challenges regarding epigenetic research, the impact of personalised medicine on patients and communication in science, particularly within our consortium and between researchers and clinicians. EpiPredict would like to invite all who are interested to attend.</p><p>To register for our event in Heidelberg, go to <a href="https://www.eventbrite.co.uk/e/everything-you-always-wanted-to-know-about-epigenetics-tickets-30118373867">Eventbrite</a>.</p><p>For more information about EpiPredict. Visit our website <a href="http://www.epipredict.eu/">http://www.epipredict.eu</a> and find us on <a href="https://www.facebook.com/EpiPredict/">Facebook</a> and <a href="https://twitter.com/epipredict">Twitter</a> @EpiPredict.</p><p>Reference:</p><p><a href="http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics">http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fd41b276f9dc" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>